Funxional Therapeutics (FXT) was formed in August 2005, as a spin-out from the French pharmaceutical group Ipsen and Cambridge University, with a management team assembled by Total Medical Ventures.
FX125L is the most advanced candidate in a new class of anti-inflammatory drugs, called somatotaxins. These drugs target a newly discovered pathway involved in the resolution of inflammation. In healthy subjects this pathway prevents chronic inflammation that results in tissue damage, but in patients with inflammatory diseases the natural ligand in this pathway is present at reduced levels, and resolution does not occur. FX125L mimics this natural ligand, and offers the potential to prevent chronic inflammation with a superior safety profile to existing therapeutic options. At the time of the transaction, FX125L was in Phase 2 clinical development for asthma, COPD, RA and psoriasis.
The company is currently evaluating several new preclinical development programmes. FX125L was sold to Boehringer Ingelheim in July 2012, while in Phase 2 development for the treatment of asthma, COPD, psoriasis and rheumatoid arthritis.